.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Novartis
Cerilliant
McKesson
Chubb
Fish and Richardson
Cipla
Mallinckrodt
US Army
Express Scripts

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:2-methyl-thieno-benzodiazepine formulation
Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
Inventor(s): Allen; Douglas J. (Indianapolis, IN), Dekemper; Kurt D. (Franklin, IN), Ferguson; Thomas H. (Greenfield, IN), Garvin; Stuart J. (Plainfield, IN), Murray; Linda C. (Noblesville, IN), Brooks; Norman D. (Greenfield, IN), Bunnell; Charles A. (Lafayette, IN), Mascarenhas; Snehlata S. (Indianapolis, IN), Shinkle; Sharon L. (Indianapolis, IN), Hendriksen; Barry A. (Guildford, GB), Tupper; David E. (Reading, GB), Sanchez-Felix; Manuel V. (Grayshott, GB)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Filing Date:Jul 03, 2003
Application Number:10/613,619
Claims:1. A formulation comprising olanzapine pamoate monohydrate as an active ingredient and one or more carriers selected from the group consisting of an oleaginous carrier and cholesterol microsphere carrier wherein said formulation has a prolonged sustained release of greater than 7 days and up to 30 days, and a burst release of less than 15% of the active ingredient.

2. A formulation as claimed in claim 1 wherein said carrier is oleagenous.

3. A formulation as claimed by claim 1 wherein the formulation further comprises one or more pharmaceutically acceptable excipients.

4. A formulation as claimed by claim 3 wherein the pharmaceutically acceptable excipient is selected from the group consisting of a gelling agent and an antihydration agent.

5. A formulation as claimed in claim 1 wherein the carrier is a cholesterol microparticle.

6. A formulation as claimed in claim 5 wherein the microparticle is a microsphere.

7. A formulation as claimed in claim 5 wherein the cholesterol is selected from the group consisting of cholesterol, cholesterol palmitate, cholesterol oleate, cholesterol stearate, and cholesterol hemisuccinate.

8. A formulation as claimed in claim 5 wherein the microspheres have a particle size of from 20 to 500 .mu.m.

9. A formulation as claimed in claim 8 wherein the particle size is from 30 to 200 .mu.m.

10. A formulation as claimed in claim 6 wherein the particle size is from 40 to 100 .mu.m.

11. A formulation as claimed in claim 5 wherein the microspheres are administered in an oleaginous carrier.

12. A formulation as claimed in claim 1 wherein the active ingredient is milled.

13. A formulation comprising olanzapine pamoate monohydrate as an active ingredient, and one or more carriers.

14. A formulation as claimed in claim 13 wherein the olanzapine pamoate monohydrate has a particle size of from about 20 to about 60 .mu.m.

15. A formulation as claimed in claim 13 wherein the olanzapine pamoate monohydrate has a particle size of from about 5 to about 20 .mu.m.

16. A formulation as claimed in 13 wherein said formulation has a prolonged sustained release of greater than 7 days and up to 30 days, and a burst release of less than 15% of the active ingredient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
US Army
Moodys
AstraZeneca
Cerilliant
Healthtrust
Dow
Novartis
Accenture
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot